Clinical Trials at Urology of VirginiaOur staff’s experienced investigators and certified clinical research coordinators closely monitor participating patients during the course of a study period. All clinical trials are conducted according to the principles of Good Clinical Practice (GCPs) as mandated by the FDA.
For questions and information about our clinical trials, please contact us at research@urologyofva.net
There is a new research study in Virginia Beach for men living with BPH (enlarged prostate).
No cost to participate. Learn more. 757-452-3463.
- Participants have access to advanced medications or devices before they become available to the public.
- Clinical study procedures may be provided to you at no cost.
- Participants often express enthusiasm for contributing to medical science.
- Today’s clinical research can positively impact future generations.
Enrolling Clinical Studies at Urology of Virginia
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B).
Get detailed information about this clinical trial»
Ferring ABLE-41: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
Multi-center, prospective non-interventional study to collect data on the early use of ADSTILADRIN in the US. Data will be collected from participants, caregivers and prescribing physicians in a real-world setting.
Get detailed information about this clinical trial»
Janssen SunRISe-2: A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.
Get detailed information about this clinical trial»
Janssen SunRISe-3: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer
The purpose of this study is to compare event-free survival (EFS) in patients with BCG-naïve high-risk, non-muscle invasive (HR-NMIBC), between TAR-200 plus cetrelimab and TAR-200 alone versus intravesical BCG.
Expected Management
Canary PASS:
A multicenter, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate cancer at diagnosis. The objective is to discover and confirm biomarkers that predict aggressive disease.
Hormone Therapy (ADT)/ Other Treatments
Francis Medical VAPOR2: Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device (“Vanquish”) in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Get detailed information about this clinical trial»
Myovant OPTYX: A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX (OPTYX)
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
Get detailed information about this clinical trial»
Myovant REPLACE-CV: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
This is a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. This study will collect clinical and cardiovascular risk factor data on patients ages 18 and older who are receiving relugolix or leuprolide acetate for their prostate cancer or as adjunct to radiation therapy with a treatment plan to be on androgen deprivation therapy (ADT) for at least one year.
Get detailed information about this clinical trial»
Metastatic disease: Cancer that has spread to other areas
Janssen LIBERTAS: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
The purpose of the study is to determine if the intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) after 6 months of treatment with apalutamide and ADT combination therapy provides non-inferior radiographic progression-free survival (rPFS) and a reduced burden of hot flashes.
BPH (Enlarged Prostate)
Prodeon EXPANDER-2: A Randomized Study to Evaluate the Safety and Efficacy of the Urocross(TM) Expander System and Retrieval Sheath
To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).
Get detailed information about this clinical trial»
Proverum ProVIDE: ProVee Urethral Expander System IDE Study
A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH).
Get detailed information about this clinical trial»
Hypogonadism/Low Testosterone
No Enrolling Studies at This Time
Incontinence
No Enrolling Studies at This Time
Interstitial Cystitis
No Enrolling Studies at This Time
Nocturia
No Enrolling Studies at This Time
Pelvic Organ Prolapse
No Enrolling Studies at This Time
Stone Disease
No Enrolling Studies at This Time
Urethral Stricture
No Enrolling Studies at This Time